Triple-hit therapeutic approach for triple negative breast cancers using docetaxel nanoparticles, EN1-iPeps and RGD peptides

Anabel Sorolla, Edina Wang, Tristan D. Clemons, Cameron W. Evans, Janice HC Plani-Lam, Emily Golden, Ben Dessauvagie, Andrew D. Redfern, K. Swaminathan-Iyer, Pilar Blancafort

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Triple negative breast cancers (TNBC) are aggressive malignancies for which chemotherapy is the only treatment option. Many TNBC acquire chemotherapy resistance, notably docetaxel, which has been associated with the overexpression of transcription factors (TFs), such as ENGRAILED1 (EN1). Here, we have developed a tumor delivery system for docetaxel-PGMA-PAA-nanoparticles and interference peptides designed to specifically inhibit EN1 (EN1-iPeps). To promote tumor specific targeting, we functionalized these nanoparticles with EN1-iPeps engineered with RGD sequences. We found that these peptides reduce cell viability and induce apoptosis in TNBC cells with negligible effects on normal cells (EN1). Moreover, EN1-RGD-iPeps-mediated nanoparticle internalization into breast cancer cells was via integrins and intravenous injection of this nanoformulation increased tumor accumulation. Furthermore, docetaxel nanoparticles functionalized with EN1-RGD-iPeps significantly reduced TNBC growth both in vitro and in vivo without showing toxicity. Our results suggest that this targeted nanoformulation represents a new and safe therapeutic approach for chemoresistant TNBCs.

Original languageEnglish
Article number102003
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume20
DOIs
Publication statusPublished - 1 Aug 2019

Fingerprint Dive into the research topics of 'Triple-hit therapeutic approach for triple negative breast cancers using docetaxel nanoparticles, EN1-iPeps and RGD peptides'. Together they form a unique fingerprint.

Cite this